Cyborg Garden · Open Science · Experiment 011

The Pirate Pharmacy Question: which medicine can a community actually make?

Sequences are already downloadable; safe injectables are not. We scored nine domains of medicine on societal benefit against demonstrated small-scale feasibility — and the binding constraint is almost never chemistry. It is sterility and quality control.

✓ 14 citations · 4-axis verified (Crossref / OpenAlex / retraction) ✗ 1 frequently-cited review caught as RETRACTED and excluded landscape synthesis · 2026-09-24

The question

Between AI-designed CRISPR-like enzymes and projects like the Four Thieves Vinegar Collective, there is a visible gap: medicine could be far more democratized than it is. mRNA vaccine sequences are, in principle, downloadable — you could imagine an mRNA-vaccine Pirate Bay. The hard part, as the intuition goes, is turning a sequence into a safe injectable. So: which areas of medicine offer the most low-hanging societal benefit and are producible, now or soon, at city-to-homebrew community scale?

We treated that as a research question rather than a vibe. The method: scope nine candidate domains, gather from both the academic record and the pirate/biohacker grey literature, verify every academic citation against Crossref and OpenAlex (existence, metadata, retraction, URL), attribute community claims to primary pages, and score each domain on two axes plus one gate.

The gate. Every domain is filtered through one question: can it be made sterile and verifiably pure at community scale? That — not synthesis — is what separates a downloaded recipe from a safe medicine, and it recurs in every single row below.
T-A
Now, real. Produced outside incumbent pharma today, with working exemplars.
T-B
2–7 years. Platform demonstrated at bench/POC; needs engineering + QC, not new science.
T-C
7+ years or gated. Possible, but blocked on sterility, QC, or regulation at small scale.

The landscape, ranked by ripeness

DomainReadinessWhat exists / what's demonstratedThe gate
Open devices & diagnostics
stethoscopes, tourniquets, microscopes, centrifuges
 T-A · now Glia Project's $2.83 3D-printed stethoscope (validated vs. Littmann, deployed in Gaza) and ~$7 tourniquet; Prakash lab's ~$1 Foldscope microscope and hand-powered Paperfuge centrifuge (125,000 rpm, plasma in ~90 s).Cybulski 2014, PLoS ONE · Bhamla 2017, Nat Biomed Eng None — external/last-contact devices, no sterility or cold-chain gate. Highest benefit-per-effort in the whole landscape.
Small molecules via legal compounding
pharmacy-scale generics & repurposed drugs
 T-A · now US 503A/503B compounding already permits patient/clinic-scale preparation without full cGMP; Cost-Plus/non-profit generics show the manufacturing economics were never the barrier — the pricing/IP layer was. Regulatory, not scientific. Democratization here is a logistics-and-law problem.
Homebrew / compounded hormones
the trans DIY-HRT ecosystem
 T-A · now (grey) The largest real-world community-scale injectable producer ecosystem: raw-API sourcing + homebrew compounding, with shared harm-reduction norms and community blood-testing.diyhrt.wiki (primary); sociological studies in Stanford Digital Repository & Soc Sci Med 2024 Works because estradiol is a forgiving, stable small molecule — but carries exactly the sterility risk that defines the gate; the community itself recommends pharma-grade where available.
Cell-free protein synthesis (CFPS)
the pivotal platform for downloadable biologics
 T-B · 2–7 yr Freeze-dried cell-free expression on paper ("just add water"); point-of-care peptide-hormone production; cell-free insulin in under a day (Borhani 2025); thermostable CFPS for conjugate vaccines; on-demand G-CSF that passed an in-vivo mouse safety/efficacy bar.Pardee 2016, Cell · DeWinter 2023, ACS Synth Biol · Borhani 2025, bioRxiv · Warfel 2023, ACS Synth Biol · Adiga 2020, Biotechnol Prog Abiotic (no live-culture containment) and freeze-dried (no cold chain) — but does NOT yet solve GMP-grade purity/endotoxin or regulatory acceptance for human injection.
CRISPR point-of-care diagnostics
SHERLOCK · DETECTR · miSHERLOCK
 T-B · 2–7 yr Attomolar, isothermal nucleic-acid detection (SHERLOCK, DETECTR); miSHERLOCK makes it a low-cost saliva-in, ~1-hour visual-readout SARS-CoV-2 device.Gootenberg 2017, Science · Chen 2018, Science · Kellner 2019, Nat Protoc · de Puig 2021, Sci Adv No therapeutic sterility gate — diagnostics can decentralize far faster than therapeutics. Caution: a much-cited 2021 J Clin Microbiol review of these tools is retracted (verified via Retraction Watch); rely on the primary papers.
On-demand small-molecule hardware
continuous-flow "pharmacy on demand" · Apothecary MicroLab
 T-B · 2–7 yr MIT's DARPA-funded fridge-sized reconfigurable continuous-flow system (hundreds–thousands of doses/day); Four Thieves' Apothecary MicroLab with a published pyrimethamine/Daraprim synthesis.Adamo 2016, Science · Four Thieves Vinegar Collective documentation (primary) The most "Pirate-Bay" domain — small molecules are downloadable recipes — but residual solvents, isomers, and dosing QA keep outputs research-grade, not clinical.
mRNA vaccines
the headline case
 T-C · 7+ yr (facility) The sequence is trivially downloadable. But a safe injectable needs clean capping, LNP formulation (the real secret sauce, not the sequence), and sterile fill-finish. Academic decentralization (WHO tech-transfer hub, modular "BioNTainer"-class units, Mobile-On-Demand preprints) targets country/facility scale, not homes.Mukherjee 2023, PLOS Glob Public Health Sterile fill-finish + LNP QC is the rate-limiting step. The two real "homebrew vaccine" attempts are cautionary: RaDVaC (untested DIY nasal vaccine, no efficacy data) and Johnny Stine (DOJ/FDA criminal charges, 2020).
Monoclonal antibodies & complex biologics T-C · 7+ yr Expressible in engineered yeast/microbial systems (the Open Insulin precedent), but purification + QC + immunogenicity at small scale keeps it out of community reach.Open Insulin Foundation — own status: "still working primarily on technology R&D… some time before manufacturing" Same QC wall as mRNA, with an added immunogenicity problem.
Morphological-freedom biotech
the Freedom of Form Foundation case
 T-C · early (but feasible) The Freedom of Form Foundation's SynthFur project announced (Sept 2026) the first live-subject demonstration of a synthetic-fur implant — a tissue-integrating anchor — in 2 consenting subjects, with early biocompatibility data; ~2050 roadmap to anthropomorphic transition.freedomofform.org, Sept 2026 newsletter (primary) Feasible at community scale precisely because it dodges the therapeutic regulatory track (consenting body-mod, not a licensed therapeutic). Low public-health benefit — watch it as a leading indicator, don't prioritize.

Predictions

Written to be falsifiable. Dates are horizons, not deadlines.

  1. ~5 yearsCell-free protein synthesis becomes the dominant decentralized-biologics platform for peptides and small proteins (insulin class first), because it is abiotic, freeze-dried, and modular. The Borhani 2025 cell-free-insulin result is the inflection artifact.
  2. structuralThe binding constraint shifts from "can we make it" to "can we certify it." The winning community infrastructure will be open QC/assay reference labs (potency, purity, endotoxin, sterility) — a "QC commons" — far more than any new synthesis hardware.
  3. ~decadeDevices and diagnostics keep outpacing therapeutics, because they avoid the sterility and therapeutic-index gate. Highest benefit-per-effort in the landscape.
  4. structuralSmall-molecule democratization runs through the legal compounding / non-profit-generic channel, not piracy. Pirate synthesis (Four Thieves) stays a forcing function and protest artifact.
  5. near-term riskA serious adverse event from homebrew injectables is the likeliest shock and will trigger regulatory tightening. The community that survives is the one that invested in open QC before the event.
  6. ~decademRNA stays facility-scale. Downloadable sequences proliferate; safe injectable LNP product does not follow them down to community scale until LNP formulation/QC is productized — a solvable but unsexy engineering problem.

Focus priorities

Ranked by expected societal benefit per unit effort, with the sterility/QC gate as the deciding factor.

  1. Open QC / analytics commons. Cheap, open assays for potency, purity, endotoxin, and sterility that any community lab can run. This is the single highest-leverage build in the whole landscape — it converts "made it" into "safe to use," and no incumbent is building it.
  2. Productize CFPS peptide/protein production — take DeWinter / Borhani / Warfel from bench to a documented, open, reproducible community protocol with a QC envelope. Insulin is the flagship.
  3. Scale open devices and diagnostics — the boring scale-out of Glia-type devices, Foldscope/Paperfuge-class tools, and miSHERLOCK-style CRISPR point-of-care tests.
  4. Support the legal compounding / small-molecule track — open synthesis + compounding standards for high-value small molecules; nearest-term and already legal.
  5. Small-scale sterile fill-finish + formulation QC engineering — the unglamorous true bottleneck for any injectable (mRNA, insulin, hormones). Micro-scale aseptic fill-finish and LNP formulation QC is the research target that unlocks the pirate-vaccine scenario safely.
  6. Watch, don't prioritize: morphological-freedom biotech — scientifically interesting and community-scale feasible, but low public-health benefit.
Why QC is priority #1. In every domain above, synthesis turned out to be the easy half. CFPS removes live-culture containment; continuous flow removes reactor scale; compounding law removes the discovery cost. What remains — endotoxin clearance, potency assay, sterility, dosing verification — is a standards-and-instrumentation problem that is solvable in the open, and that no one currently owns. That is the gap worth filling.

Verified bibliography

Every academic reference was checked against Crossref and OpenAlex for existence, metadata match, and retraction. Two DOIs initially supplied from memory were wrong (one resolved to a different paper entirely, one was fabricated) and were corrected by searching for the real records before use — which is exactly why the check is non-optional.

#CitationDOIVerdict
1Pardee K, Slomovic S, Nguyen PQ, et al. Portable, On-Demand Biomolecular Manufacturing. Cell 2016;167(1):248–259.10.1016/j.cell.2016.09.013verified
2DeWinter MA, Thames AH, Guerrero L, Kightlinger W, Karim AS, Jewett MC. Point-of-Care Peptide Hormone Production Enabled by Cell-Free Protein Synthesis. ACS Synth Biol 2023;12(4):1216–1226.10.1021/acssynbio.2c00680verified
3Borhani SG, Levine MZ, Gurramkonda C, et al. On-demand insulin manufacturing using cell-free systems with an "on-column" conversion approach. bioRxiv 2025.10.1101/2025.04.08.633785verified · preprint
4Warfel KF, Williams A, Wong DA, et al. A Low-Cost, Thermostable, Cell-Free Protein Synthesis Platform for On-Demand Production of Conjugate Vaccines. ACS Synth Biol 2023;12(1):95–107.10.1021/acssynbio.2c00392verified
5Adiga R, Andar A, Borhani S, et al. Manufacturing biological medicines on demand: Safety and efficacy of granulocyte colony-stimulating factor in a mouse model of total body irradiation. Biotechnol Prog 2020;36(1):e2970.10.1002/btpr.2970verified
6Adamo A, Beingessner RL, Behnam M, et al. On-demand continuous-flow production of pharmaceuticals in a compact, reconfigurable system. Science 2016;352(6281):61–67.10.1126/science.aaf1337verified
7Gootenberg JS, Abudayyeh OO, Lee JW, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2 (SHERLOCK). Science 2017;356(6336):438–442.10.1126/science.aam9321verified
8Chen JS, Ma E, Harrington LB, et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity (DETECTR). Science 2018;360(6387):436–439.10.1126/science.aar6245verified
9Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F. SHERLOCK: nucleic acid detection with CRISPR nucleases. Nat Protoc 2019;14(10):2986–3012.10.1038/s41596-019-0210-2verified
10de Puig H, Lee RA, Najjar D, et al. Minimally instrumented SHERLOCK (miSHERLOCK) for CRISPR-based point-of-care diagnosis of SARS-CoV-2 and emerging variants. Sci Adv 2021;7(32):eabh2944.10.1126/sciadv.abh2944verified
11Bhamla MS, Benson B, Chai C, Katsikis G, Johri A, Prakash M. Hand-powered ultralow-cost paper centrifuge. Nat Biomed Eng 2017;1:0009.10.1038/s41551-016-0009verified
12Cybulski JS, Clements J, Prakash M. Foldscope: Origami-Based Paper Microscope. PLoS ONE 2014;9(6):e98781.10.1371/journal.pone.0098781verified
13Greene JA, Riggs KR. Why Is There No Generic Insulin? Historical Origins of an American Problem. N Engl J Med 2015;372(12):1171–1175.10.1056/NEJMms1411398verified
14Mukherjee S, Kalra K, Phelan AL. Expanding global vaccine manufacturing capacity: Strategic prioritization in small countries. PLOS Glob Public Health 2023;3(6):e0002098.10.1371/journal.pgph.0002098verified
✗Excluded — retracted. Mustafa MI, Makhawi AM. SHERLOCK and DETECTR: CRISPR-Cas Systems as Potential Rapid Diagnostic Tools for Emerging Infectious Diseases. J Clin Microbiol 2021;59(3):e00745-20.10.1128/jcm.00745-20RETRACTED 2023

Primary community / grey sources (attributed, not peer-reviewed)

Open Insulin Foundation (openinsulin.org) · Four Thieves Vinegar Collective — EpiPencil & Apothecary MicroLab, subject of a 2016 FDA warning · Freedom of Form Foundation (freedomofform.org, SynthFur Sept 2026) · DIY-HRT community (diyhrt.wiki) · Glia Project (glia.org) · Cautionary enforcement: DOJ W.D. Wash. — Johnny Stine charged 2020; RaDVaC DIY nasal-vaccine self-experimentation (MIT Tech Review / Sci Am 2020).

Method & integrity. Landscape synthesis by Matilde, 2026-09-24. All academic citations 4-axis verified (existence, metadata, retraction, URL) against Crossref/OpenAlex; community claims attributed to primary pages and labeled claim-vs-demonstrated. The single largest uncertainty across the whole report is QC/sterility at community scale, which is why it anchors both the predictions and priority #1. One frequently-cited review was caught as retracted during verification and excluded rather than laundered into authority.